



ASX Announcement
Invitrocue Limited (ASX:IVQ)

Invitrocue Clinical validation studies underway in Germany

Paves way to treat European patients

Highlights

- Commenced clinical validation with Klinikum Rechts der Isar der Technischen Universität München, Comprehensive Cancer Center Munich, Germany.
- Study uses IVQ's personalised oncology approach to evaluate the effect of cancer drugs on the patients' own unique tumour cells in the lab.
- Results from cohort 1 of the study are expected within the next quarter and initial results are positive.

24 September 2019: Innovative life sciences company **Invitrocue Limited (ASX: IVQ) ('Invitrocue' or 'the Company')** is pleased to announce that a clinical validation study is underway for its Onco-PDO™ test with Klinikum Rechts der Isar der Technischen Universität München, Comprehensive Cancer Center Munich, Germany.

The study, titled IVQ-Rechts der Isar Validation Study 2019, will establish patient-derived organoids (PDOs) using biopsy samples taken from patients with high-risk breast cancer. The PDOs will be tested against a panel of cancer drugs (including standard of care drugs). Drug responses in PDOs will then be compared to the responses of actual patients undergoing chemotherapy treatment in the clinic. The results will serve as an indication of the predictive value of the Onco-PDO™ test for personalized cancer treatment.

How IVQ's technology benefits cancer patients

Most cancer treatments today have a "one-size-fits-all" approach where different patients are given the same cancer drugs. The Onco-PDO™ technology will allow scientists at IVQ to test patient-derived organoids against a panel of chemotherapeutic drugs. The results will allow physicians to make a more informed decision about the most appropriate cancer drugs and treatment regimen for that individual patient. This potentially eliminates unnecessary side effects from futile treatments, saves precious time for the patient and reduces costs for the healthcare system.

Study may benefit many European cancer patients

The study is an important step for Invitrocue as it will potentially allow the Company's personalised oncology approach to benefit cancer patients in Europe. Germany alone had 608,742 new cancer cases in 2018, with 11.8% being breast cancer cases.¹

The first cohort of the study consists of 20 patients, with results expected within Q3 of 2019. Initial results have been positive. The second cohort consists of 60 patients.

¹ Globocan 2018, World Health Organization.



Prof. Dr. Marion Kiechle, director of the Department of Gynecology at the Klinikum Rechts der Isar and Dr Stefan Paepke, Head of Interdisciplinary Breast Center, are leading the study.

Dr Steven Fang, Executive Chairman of Invitrocue, said: “We are pleased to be starting the first clinical study in Germany to clinically test the feasibility and effectiveness of Invitrocue’s Onco-PDO technology. This trial will validate our belief that Invitrocue’s technology can revolutionise the ability of oncologists to give the right drugs to the right patients at the right time. We are honoured to be working on this study with Prof Dr Marion Kiechle and Dr Stefan Paepke at a leading clinic such as Munich’s Rechts der Isar Hospital, and look forward to keeping all of our stakeholders updated on the progress of this important study.”

Ends

For further information, please contact:

Invitrocue

Martin D. Bach

VP Operations

M: +65 6460 0497

E: martind.bach@invitrocue.com

Media & investor enquiries

Julia Maguire

The Capital Network

M: +61 419 815 386

E: julia@thecapitalnetwork.com.au

www.invitrocue.com

About Invitrocue (ASX:IVQ)

Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue’s Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ.

To learn more, please visit: www.invitrocue.com

About Klinikum Rechts der Isar der Technischen Universität München, Comprehensive Cancer Center

Klinikum rechts der Isar is the university hospital of the Technical University Munich (TUM). Founded in 1834, the University Hospital rechts der Isar today stands for state-of-the-art medicine, research & advancement. Approximately 5,500 people work at the hospital, whether in the provision of medical care, research or teaching. Every year, more than 60,000 patients benefit from hospitalized care in addition to around 250,000 patients receiving outpatient treatment. With roughly 30 departments, 20 interdisciplinary centers and 1,161 beds, the hospital offers the entire range of modern medical treatments. In addition, research into diseases and new therapeutic options is undertaken at numerous scientific institutes.

The Comprehensive Cancer Center Munich TUM is an interdisciplinary center dedicated to cancer research and therapy. It is part of the Comprehensive Cancer Center Munich (CCCM), one of Germany’s 13 oncology centers of excellence supported by German Cancer Aid.